1887

Abstract

. This study was conducted to understand the effect of fosfomycin in combination with amikacin, ciprofloxacin or meropenem on biofilm formation by multidrug-resistant urinary isolates of .

Fifty urinary tract multidrug-resistant isolates that were known biofilm producers were studied. The MIC was determined using the agar dilution method for amikacin, ciprofloxacin, meropenem and fosfomycin. The fractional inhibitory concentration was determined for the combination of antibiotics followed by a time-kill assay. A tissue culture plate method was used to study the effect of the combination of antibiotics on biofilm formation.

The MICs of the isolates tested ranged from 0.25 to 32 µg ml for fosfomycin, 1 to 1024 µg ml for ciprofloxacin, 4 to 1024 µg ml for amikacin, and 0.25 to 512 µg ml for meropenem. The combination of fosfomycin with meropenem showed 68 % synergy, fosfomycin with amikacin 58 % synergy and fosfomycin with ciprofloxacin 6 % synergy. The combination also reduced the MIC of each antibiotic and none showed an antagonistic effect. Biofilm inhibition was best observed with the combination of fosfomycin with meropenem.

The combination of fosfomycin with amikacin and fosfomycin with meropenem yielded a high percentage of synergy alongside an increased capacity to reduce biofilm formation when compared to combination with ciprofloxacin against multidrug-resistant . Fosfomycin in combination with other classes of antimicrobial agents has potential beneficial effects.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001061
2019-10-24
2019-11-12
Loading full text...

Full text loading...

References

  1. Catheter-associated Urinary Tract Infections (CAUTI). 2017; https://www.cdc.gov/hai/ca_uti/uti.html cited 2018 Dec 26
  2. Kumar D, Das A, Purbey M, Gupta N, Nath G. Susceptibility of uropathogenic multidrug-resistant Escherichia coli to fosfomycin. J Acad Clin Microbiol 2017;19: 101 [CrossRef]
    [Google Scholar]
  3. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010;10: 597– 602 [CrossRef]
    [Google Scholar]
  4. Brady AJ, Laverty G, Gilpin DF, Kearney P, Tunney M. Antibiotic susceptibility of planktonic- and biofilm-grown staphylococci isolated from implant-associated infections: should MBEC and nature of biofilm formation replace MIC?. J Med Microbiol 2017;66: 461– 469 [CrossRef]
    [Google Scholar]
  5. Beloin C, Roux A, Ghigo JM. Escherichia coli biofilms. Curr Top Microbiol Immunol 2008;322: 249– 289
    [Google Scholar]
  6. Silver LL. Fosfomycin: mechanism and resistance. Cold Spring Harb Perspect Med 2017;7: a025262 [CrossRef]
    [Google Scholar]
  7. Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ, Fosfomycin VKZ. Fosfomycin. Clin Microbiol Rev 2016;29: 321– 347 [CrossRef]
    [Google Scholar]
  8. Shi J, Mao N-F, Wang L, Zhang H-B, Chen Q et al. Efficacy of combined vancomycin and fosfomycin against methicillin-resistant Staphylococcus aureus in biofilms in vivo. PLoS One 2014;9: e113133 [CrossRef]
    [Google Scholar]
  9. Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007;13: 285– 290 [CrossRef]
    [Google Scholar]
  10. Marchese A, Bozzolasco M, Gualco L, Debbia EA, Schito GC et al. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents 2003;22 Suppl 2: 95– 100 [CrossRef]
    [Google Scholar]
  11. Descourouez JL, Jorgenson MR, Wergin JE, Rose WE. Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents. Antimicrob Agents Chemother 2013;57: 1518– 1520 [CrossRef]
    [Google Scholar]
  12. CLSI Performance Standards for Antibiotic Susceptibility Testing2017, 27th Edition, CLSI supplement M100. Wayne, PA: Clinical Laboratory Standards Institute; 2017
    [Google Scholar]
  13. Lorian V. editor Antibiotics in Laboratory Medicine, 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005
    [Google Scholar]
  14. Tessier F, Quentin C. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 1997;16: 159– 162 [CrossRef]
    [Google Scholar]
  15. Kastoris AC, Rafailidis PI, Vouloumanou EK, Gkegkes ID, Falagas ME. Synergy of fosfomycin with other antibiotics for gram-positive and gram-negative bacteria. Eur J Clin Pharmacol 2010;66: 359– 368 [CrossRef]
    [Google Scholar]
  16. Christensen GD, Simpson WA, Younger JJ, Baddour LM, Barrett FF et al. Adherence of coagulase-negative staphylococci to plastic tissue culture plates: a quantitative model for the adherence of staphylococci to medical devices. J Clin Microbiol 1985;22: 996– 1006
    [Google Scholar]
  17. Petersen PJ, Labthavikul P, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006;57: 573– 576 [CrossRef]
    [Google Scholar]
  18. Matthews PC, Barrett LK, Warren S, Stoesser N, Snelling M et al. Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. BMC Infect Dis 2016;16: [CrossRef]
    [Google Scholar]
  19. Evren E, Azap OK, Çolakoğlu Şule, Arslan H, Azap Özlem Kurt, ÖK A. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis 2013;76: 335– 338 [CrossRef]
    [Google Scholar]
  20. Cai Y, Fan Y, Wang R, An M-M, Liang B-B. Synergistic effects of aminoglycosides and fosfomycin on Pseudomonas aeruginosa in vitro and biofilm infections in a rat model. J Antimicrob Chemother 2009;64: 563– 566 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001061
Loading
/content/journal/jmm/10.1099/jmm.0.001061
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error